Skip to content

Can a Personalized Education Program Help People with Rheumatoid Arthritis Take Their Medicines Better and Feel Healthier?

Impact of a Tailored Multimodal Educational Intervention on Medication Adherence and Rheumatoid Arthritis Disease Activity: A Randomized, Parallel-Group, Interventional Study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091183
Enrollment
66
Registered
2025-07-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: Tailored Multimodal Educational Intervention on Medication Adherence and Rheumatoid Arthritis Disease Activity: The intervention group will receive a tailored multimodal education progr

Sponsors

Dr Chaitali A Chindhalore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of rheumatoid arthritis according to the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria Patients of an either gender with age more than 18 years On stable dose of anti-rheumatoid medication for 4 weeks prior to enrolment in study Ability to provide written informed consent. Willingness to participate in educational sessions and adhere to study protocols. Proficiency in the local language or English to understand educational materials.

Exclusion criteria

Exclusion criteria: I. Severe cognitive impairment or psychiatric conditions that may interfere with study participation. II. Patient suffering from severe chronic illness which may affect the disease outcome/compliance. III. Concurrent participation in other interventional studies related to RA management. IV. Pregnancy or breastfeeding, as these conditions may affect medication regimens and disease activity. V. History of non-adherence to medical appointments or inability to attend follow-up visits

Design outcomes

Primary

MeasureTime frame
Mean changes in CQR 19 score at week 12 in both groups.Timepoint: 12 weeks

Secondary

MeasureTime frame
Change in CQR 19 score from baseline to week 6, and week 12 in both groups.Timepoint: 0 to 6 weeks and 12 weeks;Change in Disease activity score (DAS) from baseline to week 6 and week 12 in both the groups.Timepoint: 12 weeks;Proportion of patients achieving remission in both the groupsTimepoint: 12 weeks;To study the impact of various sociodemographic variables along with medication adherence on disease activityTimepoint: 12 weeks

Countries

India

Contacts

Public ContactSanjaya Dhal

AIIMS Nagpur

sanjaydhal2017@gmail.com7978692609

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026